Qing Dong

Mr. Dong is a passionate drug hunter with more than 25 years of experience in drug discovery. He has particular strength in the structure-based design of oncology and inflammation drug candidates and has contributed to five marketed drugs and more than 15 clinical phase compounds. Prior to co-founding XinThera in 2021 along with Stephen Kaldor, Ph.D., and Gene Hung, M.D., he co-founded small molecule inflammation biotech FronThera in 2015 and served as its President & CSO through its successful acquisition in February 2021. From 2010 to 2015, Mr. Dong was CSO at Hengrui and played an integral role in building this leading Chinese pharmaceutical company’s small molecule portfolio. Earlier in his career, he worked as a medicinal chemist at both Takeda and Triad Therapeutics.

Mr. Dong received his Ph.D. in organic chemistry at Rice University and completed his post-doctoral training at Harvard Medical School.